Currently browsing tag

northern

Novartis and Xencor enter into bispecific antibody agreement

Novartis has received rights with Xencor to develop bispecific antibodies for treating cancer. “Under the terms of the agreement, Xencor is receiving a $150 million upfront payment from Novartis and the two companies will equally share the cost to jointly develop two Xencor antibodies targeting the CD3 domain,” Novartis said. Novartis would additionally receive rights to develop and commercialize four further bispecific antibodies and to use Xencor's antibody technology in up to 10 additional molecules, the companies said.

Rat poison sales boom in Nigeria over Lassa fever fears

Sales of rat poison have taken off in Nigeria following an outbreak of Lassa fever that has left at least 76 people dead and sparked fears of contagion across the country. In the northern city of Kano, the capital of one of 17 states where the haemorrhagic virus has been recorded, there have been “unprecedented” purchases of the pest control product. The head of the city's chemicals traders, Shehu Idris Bichi, said sales have have increased four-fold since the outbreak was first announced earlier this month.

Novartis buys another 2.5 percent in Israel’s Gamida Cell

Swiss drugmaker Novartis will invest up to an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said on Sunday. Novartis last year invested $35 million in the company for a 15 percent stake, in a deal that could reach $600 million if Novartis exercises a buyout option that expires in 2016. The $15 million investment will be used to advance Gamida Cell's clinical programs, including the development of NiCord, an experimental treatment for patients with high risk hematological malignancies, or blood cancers such as leukemia and lymphoma and sickle cell disease.